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ORIGINAL ARTICLE

Hepatoid Teratoma, Hepatoid Yolk Sac Tumor,
and Hepatocellular Carcinoma
A Morphologic and Immunohistochemical Study of 30 Cases
Khaleel I. Al-Obaidy, MD,* Sean R. Williamson, MD,† Nathan Shelman, MD,*
Muhammad T. Idrees, MD,* and Thomas M. Ulbright, MD*

Abstract: Rare hepatoid teratomas (HTs) in testicular germ cell tumor
patients mimic hepatoid yolk sac tumor (HYST) and hepatocellular
carcinoma (HCC). We compared the features of 2 metastatic HTs, 12
HYSTs, and 16 HCCs. The mean ages were 36, 40, and 62.5 years,
respectively. The HTs formed sheets of hepatocyte-like cells with
macrovesicular fat arranged in vague lobules with intervening ﬁbrous
bands containing biliary ductule–like structures and abortive portal
triads. HTs lacked basement membrane deposits, with hepatoid cells
staining for glypican-3, arginase, and HepPar-1 (2/2), whereas stains
for CK19 (2/2) and CK7 (1/2) highlighted ductules and for villin
hepatoid cells and ductules (1/2). SALL4 and CDX2 stains were
negative (0/2). HYSTs formed nests, trabeculae, cords, and occasional
gland-like structures, and most (10/12; 83%) produced intercellular
basement membrane. No Mallory-Denk bodies were seen. Stains for
SALL4 (100%), glypican-3 (100%), CK19 (88%), CDX2 (88%), and
villin (75%) were positive, whereas those for HepPar-1 highlighted rare
tumor cells (70%) and for arginase were mostly negative (26%). All
HCCs lacked basement membrane deposits, with Mallory-Denk
bodies occurring in 50%. Stains for HepPar-1 (100%) and arginase
(94%) were positive, glypican-3 infrequent (19%), and SALL4, CK19,
villin, and CDX2 negative. In summary, HTs are distinguished from
HYST by the formation of ductules and abortive portal tracts, lack of
basement membrane deposits, more consistent staining for arginase
and HepPar-1, and negativity for SALL4 and CDX2. Contrasting
features of HCCs with HYSTs include negativity for SALL4, CK19,
and CDX2, frequent Mallory-Denk bodies, and absence of basement
membrane deposits.
Key Words: yolk sac tumor, hepatoid yolk sac tumor, teratoma,
hepatoid teratoma, hepatocellular carcinoma, germ cell tumors
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T

he yolk sac tumor (YST) of the testis is known for its
divergent differentiation, including the formation of
hepatocyte-like tumor cells, so-called hepatoid yolk sac
tumor (HYST).1 Although pure YST is a relatively common ﬁnding in primary testicular tumors of prepubertal
children,2 in older patients pure YST is most often found
in metastatic sites following chemotherapy and disproportionately in late recurrences many years after initial
treatment.3,4 This circumstance is especially the case for
HYST. In our practice, we discovered a potential mimicker of HYST that also occurred in metastatic sites following chemotherapy and showed striking hepatic
differentiation. These tumors, however, resembled normal
liver, showing sheets of hepatocyte-like cells with large fat
vacuoles and the formation of biliary ductules and abortive portal structures. Consequently, we felt they were best
classiﬁed as “hepatoid teratomas” (HTs). To the best of
our knowledge, comparable HTs of testicular origin have
not previously been reported, and their hepatic differentiation initially raised questions regarding their nature,
including that they were variants of HYST, independent,
well-differentiated hepatocellular carcinomas (HCCs),
surgical errors, or mislabeled specimens. The presence of
other teratomatous elements or foci of classic YST provided convincing evidence against all of the latter 3 possibilities, but HYST could not be excluded on that basis,
and we realized that future cases may not always have an
association with additional germ cell tumor elements. We,
therefore, sought to compare the clinical, pathologic, and
immunohistochemical features of HYST, HT, and HCC.

MATERIALS AND METHODS
Our institutional review board approved this study.
An electronic search was performed of our surgical pathology databases for metastatic HYST and HT. Twelve
cases of HYST and 2 cases of HT were retrieved from
pathology department ﬁles and the authors’ consultation
archives at Indiana University and Henry Ford Health
System. A control group comprised of 16 de novo HCCs
was randomly selected from the pathology archives at Indiana University. All hematoxylin and eosin–stained slides
were reviewed by 2 pathologists (T.M.U. and K.I.A.) to
conﬁrm the diagnosis. The HCC cases were additionally
reviewed by a gastrointestinal/hepatic pathologist (N.S.).

Volume 45, Number 1, January 2021

Copyright r 2020 Wolters Kluwer Health, Inc. All rights reserved.

www.ajsp.com

| 127

Al-Obaidy et al

Am J Surg Pathol

Sections of 4 µm thickness were stained with antibodies
directed against SALL4 (6E3; BioCare Medical, Pacheco,
CA), cytokeratin 7 (OV-TL 12/30; Dako, Agilent, Santa
Clara, CA), cytokeratin 19 (RCK108; Dako, Agilent),
CDX2 (DAK-CDX2; Dako, Agilent), glypican-3 (1G12;
Cell Marque, Rocklin, CA), arginase (SP156; Dako, Agilent), HepPar-1 (OCH108; Dako, Agilent), and villin (1D2
C3; Dako, Agilent) in a Dako automated instrument.
Positive and negative controls gave appropriate results for
each stain. The staining extent was recorded as negative,
focal (1+; <25%), intermediate (2+; 25% to 75%) or diffuse
(3+; > 75%), and the intensity was recorded as negative,
weak (1+), moderate (2+), or strong (3+). Only slides with
> 90% HYSTs were selected for immunohistochemical
analysis. Follow-up information and mortality data were
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obtained from patients’ electronic records and physicians’
ofﬁces.

RESULTS
Hepatoid Yolk Sac Tumor
The clinicopathologic features are summarized in
Table 1. The patient cohort consisted of 12 men. The mean and
median ages at the time of initial diagnosis were each 25 years
(range, 17 to 39 y; initial age unknown for 1 patient). All
patients had primary testicular nonseminomatous germ cell
tumors that were predominantly of mixed nature. Three had
metastases at presentation and 9 developed metastases later
in their clinical courses. The 8 patients with available data who
developed metastatic HYST after initial diagnosis and

TABLE 1. Clinicopathologic Characteristics of Cases of HYST (N = 12) and HT (N = 2)
Case
No. Age* Primary Diagnosis
HYST

HT

Source of
Hepatoid
Specimen

1

39

Testicular mixed
germ cell tumor

RPLND

2

42

RPLND

3

39

Testicular mixed
germ cell tumor
Testicular mixed
germ cell tumor

4

25

5

41

6

30

Testicular mixed
germ cell tumor

7

33

Testicular mixed
germ cell tumor

8

39

9

63

10

31

Testicular mixed
germ cell tumor
Testicular
nonseminomatous
germ cell tumor
Testicular mixed
germ cell tumor

11

20

Testicular mixed
germ cell tumor

12

34

Testicular mixed
germ cell tumor

1

36

2

44

Testicular mixed
germ cell tumor
Testicular mixed
germ cell tumor

Testicular
nonseminomatous
germ cell tumor
Testicular mixed
germ cell tumor

RPLND
Mediastinal
mass
excision
RPLND

Clinical Information and
Management After Primary
Testicular Diagnosis

Time After Presentation to Outcome (Duration
Excision of Hepatoid
After initial
Specimen
diagnosis)

History of multiple recurrences
Received multiple courses of
chemotherapy
NA

10 y

A (2 y)

NA

NA

Multiple recurrences
Received multiple courses of
chemotherapy
Received multiple courses of
chemotherapy

22 y

A (3 y)

8y

A (5 y)

23 y

A (2 y)

2y

A (1 y)

8y

A (NA)

22 y

A (4 y)

24 y

NA

NA

NA

4 mo

NA

Multiple RPLN recurrences
Received multiple courses of
chemotherapy
Mediastinal
Received multiple courses of
mass
chemotherapy.
excision
Presented with elevated level of AFP
RPLND
Received multiple courses of
chemotherapy
Presented with elevated level of AFP
RPLN biopsy Received multiple courses of
chemotherapy
Lung
Received multiple courses of
chemotherapy and RPLND
segmentectomy
Liver biopsy
Presented with multiple hepatic
lesions
Received chemotherapy after
diagnosis
RPLND
Presented with retroperitoneal
metastases
Received chemotherapy after
diagnosis
Mediastinal
Presented with retroperitoneal and
mass
mediastinal metastases
excision
Received chemotherapy after
diagnosis
RPLND
Received chemotherapy

3 mo

DOD (5 y)

6 mo

A (2 y)

RPLND

5 mo

DOD (8 mo)

History of multiple recurrences
Received multiple courses of
chemotherapy

*At the time of resection of HYST specimen.
A indicates alive; AFP, alpha-fetoprotein; DOD, died of disease; NA, not available; RPLN, retroperitoneal lymph node; RPLND, retroperitoneal lymph node dissection.
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chemotherapy did so at a median of 16 years (range, 2 to 24 y)
after presentation. The mean and median ages at the time of
resection of the HYSTs were 36 and 37 years, respectively
(range, 25 to 63 y). Follow-up data were available for 8 patients
(range, 1 to 5 y after last surgical intervention); all were alive,
except for 1 who died of disease 5 years following initial
presentation.
On microscopic examination, the tumors showed differing proportions of solid, nested, corded/trabecular, and
pseudoglandular patterns (Figs. 1A–D) that were variably
interspersed with ﬁbrous tissue that occasionally contained
eosinophilic basement membrane deposits (Fig. 1B). The
tumor cells had polygonal to columnar proﬁles and moderate
amounts of eosinophilic to clear cytoplasm that occasionally
contained large vacuoles of fat (Fig. 1B). The nuclei were
round to ovoid with vesicular to granular chromatin and
mostly single, prominent nucleoli (Fig. 1D). All tumors
showed nuclear pleomorphism and frequent mitotic ﬁgures,
often more so in solid areas, which also showed frequent foci
of tumor necrosis, although necrosis also occurred in other
areas. Foci of conspicuous intercellular basement membrane
deposits were a distinctive feature in 10/12 (83%) tumors
(Fig. 1D). No HYST formed Mallory-Denk bodies.
On immunohistochemical study (Table 2), all HYSTs
(10/10) showed strong and diffuse reactivity for antibodies
directed against SALL4 (Fig. 2A) and glypican-3 (Fig. 2B).
Staining with at least moderate intensity and focal extent for
CDX2 (Fig. 2C) (7/8, 88%) and at least weak intensity and
focal extent for CK19 (Fig. 2D) (7/8, 88%) was only slightly
less common. Stains for villin with at least moderate intensity
and intermediate extent were also positive in most cases (6/8;
75%). They highlighted cell membranes in solid areas and
luminal aspects in gland-like foci. HepPar-1 stained only a few
tumor cells in a single cell distribution in 6 tumors (55%), was
patchy positive in 2 (Fig. 2E) (18%), and negative in 3.
Immunoreactivity for arginase was less frequent, occurring in
45% of tumors (patchy in 2 and in rare cells [ < 5%] in 3)
(Fig. 2F) (5/11). CK7 was uniformly negative in all tumors
(0/9).

Hepatoid Teratoma
The clinicopathologic features are summarized in
Table 1. The patients presented at ages 36 and 44 years
with mixed germ cell tumors of the testis. Both had initial
retroperitoneal lymph node metastases and were treated
with multiple courses of cisplatin-based chemotherapy
followed by resections of residual masses in the retroperitoneum at 6 and 5 months, respectively. On follow-up, the ﬁrst
patient was alive with no evidence of disease at 24 months after
his initial presentation. The second patient received multiple
courses of chemotherapy and stem cell transplantation,
however, he died of progressive YST (see below) 8 months
following the retroperitoneal lymphadenectomy.
On microscopic examination, the HTs formed sheets of
hepatocyte-like cells subdivided by thick bands of ﬁbrous
stroma into a lobular arrangement (Fig. 3A). The tumor cells
had abundant, eosinophilic cytoplasm, round nuclei with small
nucleoli, and frequent large lipid vacuoles (Fig. 3A, inset). The
ﬁbrous bands contained occasional well (Fig. 3B) to poorly

Hepatoid Teratoma, Hepatoid Yolk Sac Tumor and HCC

formed (Fig. 3C), biliary ductule–like structures, and hemosiderin-laden macrophages. A rare portal triad was found in 1
case (Fig. 3D). Both lacked sinusoid-like spaces lined by
endothelial cells. Case 1 had associated teratomatous glial
elements and case 2 showed residual foci of classic yolk sac
tumor. Neither case showed intercellular basement membrane
deposits or Mallory-Denk bodies.
On immunohistochemical study (Table 2, Fig. 4), both
tumors were diffusely positive for glypican-3, HepPar-1, and
arginase (2/2), whereas stains for CK19 (2/2) and CK7 (1/2)
were restricted to ductular-like structures. Villin was positive in
1 tumor in both hepatocytes (membranous) and ductules
(luminal). Both HTs were negative for SALL4 and CDX2,
although the former highlighted the residual YST in case 2.

Hepatocellular Carcinoma
The clinicopathologic features are summarized in
Table 3. Sixteen HCCs were included for analysis. Tumor
size (largest nodule) ranged 3 to 24.5 cm, with a mean of
8.4 cm. Microscopic examination showed a mix of welldifferentiated (44%), moderately differentiated (50%), and
poorly differentiated (6%) neoplasms. The HCCs were
arranged in trabecular and pseudoacinar patterns. MalloryDenk bodies were seen in half (8/16), with only rare pale bodies
and ground glass change. Bile pigment was often (44%) identiﬁable in pseudoacinar structures, and intratumoral steatosis
(25%) was not uncommon. No intercellular basement membrane deposits were identiﬁed.

Immunohistochemical Analysis
The immunoreactivities are summarized in Table 2,
which shows that SALL4 positivity distinguished HYST
from both HT and HCC, as did reactivity for CDX2,
although with diminished (88%) sensitivity. Cytokeratin
19 was also useful in this regard, with frequent (88%)
reactivity in HYSTs, negativity in HCC and reactivity
limited to bile ducts in HTs. Villin was less sensitive (75%)
for HYST than CDX2 and also occurred in 1 of the HTs
in both the hepatocytes and bile duct-like structures. The
absence of arginase reactivity favored HYST over both
HT and HCC, whereas negativity for glypican-3 was
signiﬁcantly more frequent in HCC than in either HYST
or HT. We did not ﬁnd HepPar-1 or cytokeratin 7 to be
useful for differential diagnosis of these entities.

DISCUSSION
The discovery of a hepatoid neoplasm in a patient with a
history of a germ cell tumor raises several differential diagnostic
possibilities. These include HYST, hepatic differentiation of a
teratoma, and an unrelated HCC. These considerations often
have different prognostic and treatment implications. It is recognized that the presence of YST in metastases is associated
with less favorable outcomes than other forms of nonseminomatous germ cell tumor.5,6 In addition, the ﬁnding of
any form of viable nonteratomatous germ cell tumor in postchemotherapy resections is associated with reduced survival
and implies the need for additional and often intensive
chemotherapy.7 Furthermore, persistent, viable germ cell tumor (other than teratoma) in the context of “late recurrence”
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FIGURE 1. HYST showing differing proportions of solid (A), nested (B), corded/trabecular (C), and pseudoglandular (D, inset)
patterns interspersed with variably thick fibrous tissue bands (B). Prominent intercellular basement membranes deposits are noted
(D), as well as in perivascular areas (B). The cells have polygonal to columnar profiles and eosinophilic to pale cytoplasm with
moderate nuclear pleomorphism (D).

(considered 2 or more years after initial treatment),4 which
applied to at least 8 of our cases of HYST, carries an especially
poor prognosis.4 In contrast, teratoma in postchemotherapy

130 | www.ajsp.com

resections is associated with a favorable outcome and requires
no additional treatment,8 and, although there is no speciﬁc
experience with HT because of its rarity, there is also no reason
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
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HCCs

HTs

*Intensity: negative (0), weak (1+), moderate (2+), or strong (3+). Extent: negative (0), focal (1+; <25%), intermediate (2+; 25% to 75%), diffuse (3+; > 75%).
†Stained biliary ductules only.
NP indicates not performed.

94 (1.9+; 2.3+) 13 (0.1+; 0.3+)
100 (2.8+; 2.8+)
0 (0; 0)
0 (0; 0)
0 (0; 0)
19 (0.3+; 0.6+)
0 (0; 0)

3+; 3+
3+; 3+
100 (3+; 3+)
3+; 3+
3+; 3+
100 (3+; 3+)
2+; 2+
0
50 (1+; 1+)
3+; 1+†
3+; 1+†
100 (3+; 1+)
0
0
0 (0; 0)
3+; 3+
3+; 3+
100 (3+; 3+)
0
0
0 (0; 0)

1+; 1+
0
0
0
3+; 1+
2+; 1+
2+; 2+
0
0
0
NP
2+; 2+
45 (0.9+; 0.6+)
3+; 2+
3+; 1+
3+; 1+
3+; 1+
0
3+; 1+
3+; 2+
0
3+; 1+
0
NP
3+; 1+
75 (2.2+; 0.9+)
2+; 2+
0
3+; 3+
NP
3+; 3+
2+; 2+
3+; 3+
NP
NP
0
NP
3+; 2+
(2+; 1.9+)
3+; 2+
NP
3+; 2+
3+; 2+
2/3+; 2+
3+; 1+
1+; 1+
NP
NP
0
NP
3+; 2+
88 (2.3+; 1.5) 75
3+;3+
NP
3+; 2+
3+; 2+
2+; 2+
3+; 2+
3+; 3+
NP
NP
0
NP
3+; 1+
88 (2.5+; 1.9+)
3+; 3+
2/3+; 3+
3+; 3+
3+; 3+
3+; 3+
3+; 2+
3+; 3+
3+; 3+
3+; 3+
3+; 2+
3+; 3+
3+; 2+
3+; 3+
3+; 3+
3+; 3+
3+; 3+
NP
NP
3+; 3+
3+; 3+
NP
NP
3+; 3+
3+; 3+
100 (3+; 3+) 100 (3+; 2.7+)

0
3+; 1+†
50 (1.5+; 0.5+)
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1
2
3
4
5
6
7
8
9
10
11
12
% positive (mean
intensity/extent)
1
2
% positive (mean
intensity/extent)
% positive (mean
intensity/extent) N = 16
HYSTs

Glypican-3
SALL4
Case No.
Antibody (Intensity; Extent)*

TABLE 2. Immunohistochemical Characteristics of Hepatoid Tumors

CDX2

CK19

Villin

HepPar-1

Arginase

CK7

Am J Surg Pathol

Hepatoid Teratoma, Hepatoid Yolk Sac Tumor and HCC

to anticipate a behavior different from other teratomatous elements. Last, HCC is chemorefractory, but survival may be
improved in the face of metastatic disease by speciﬁc tyrosine
kinase inhibitors. It is clear, therefore, that the differentiation of
these neoplasms from one another is important.
Our study indicates features that allow the distinction of HYST from HCC. In general, HYSTs occurred
in younger patients (median, 39 y; range, 25 to 63 y)
compared to those with HCCs (median, 63.5 y; range, 49
to 79 y), although there was overlap in the age ranges.
Furthermore, HYST represented a late recurrence in at
least two-thirds of cases, occurring 2 to 24 years after the
initial diagnosis, at a median of 16 years, in this group.
Our ﬁndings are in line with those of Michael et al,4 who
found that YST was the most common tumor type in late
recurrences other than a teratoma, and hepatoid morphology occurred in 19% of those. In that series, HYST
was found 4 to 13 years after initial diagnosis (median,
8.5 y) at a median age of 31.5 years (range, 26 to 44 y).
Because of the potential for germ cell tumor recurrences to
occur as much as 40 years after initial treatment,9–11 it is
apparent that age alone cannot be used to make the distinction of HYST and HCC, especially given that age at
diagnosis of HCC has trended down in the United States
and most commonly develops in patients 30 to 50 years
old in African and Asian countries.12,13 On microscopic
examination, there is overlap between HYST and HCC;
both commonly show nested, trabecular and pseudoglandular architecture. Overt bile production strongly favors HCC over HYST; we have only seen bile in a single
example of HYST in our experience,14 whereas it occurred
in 44% of our HCCs. Mallory-Denk bodies were also restricted to HCCs and, on the other hand, foci of intercellular basement membrane deposits occurred only in
HYSTs. In difﬁcult cases, immunohistochemistry is diagnostic. HYSTs were uniformly positive for SALL4, which
is in keeping with what others have found in general
studies of YSTs,15 but our HCCs were negative, similar to
the ﬁndings in other studies that reported negative or only
rare reactivity of HCC for SALL4,16,17 although other
publications have reported a greater proportion of HCCs
with SALL4 reactivity.18 We also found that immunoreactivity for CK19, CDX2, and villin, although less sensitive than SALL4, were also speciﬁc in this differential
diagnosis, with frequent positivity in HYST and consistent
negativity in HCC.
Given the relatively bland cytologic features and the
abortive organoid morphology, with associated ﬁbrous
bands containing biliary ductule–like structures and rare
portal tract-like foci, we concluded that 2 of our cases
represented “HTs.” Teratoma is a common ﬁnding in
metastatic deposits resected after chemotherapy for testicular germ cell tumors, but we are not aware of any prior
example of metastatic testicular teratoma with hepatic
differentiation. Given that pure teratoma in retroperitoneal lymph node resections has an excellent prognosis, it is clearly important to distinguish these lesions
from both metastatic HYST and HCC. Morphology alone
is usually sufﬁcient since both HYST and HCC show
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FIGURE 2. HYSTs showing strong and diffuse nuclear immunoreactivity for SALL4 (A), and cytoplasmic positivity for glypican-3 (B),
moderate to strong nuclear immunoreactivity for CDX2 (C), and patchy cytoplasmic reactivity for CK19 (D). Only a few tumor cells
react with HepPar-1 antibody (E). Arginase immunostain shows nuclear and cytoplasmic immunoreactivity in scattered cells (F).

signiﬁcantly higher grade atypia and do not show the organoid
features of HT. Although cases of combined HCC and cholangiocarcinoma are well known, the ductular component in
these is not restricted to ﬁbrous bands but forms invasive

132 | www.ajsp.com

nodular growths. There are also immunohistochemical differences between HT and both HYST and HCC. HT, unlike
HYST, is SALL4 and CDX2 negative and more frequently
arginase positive. The highlighting of ductule-like elements by
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 3. HTs showing sheets of hepatocyte-like cells with abundant eosinophilic cytoplasm and macrovesicular fat subdivided into lobules
by fibrous bands containing hemosiderin (A). There is little cytologic atypia (A, inset). B, Well-formed biliary ductule–like structures in a fibrous
band. C, Poorly formed ductules and siderophages in a fibrous band adjacent to steatotic hepatocytes. D, A portal-like area containing a bile
duct (blue arrow), arteriole (black arrow), and venule (red arrow), with adjacent hepatocyte-like cells with macrovesicular fat.

CK19 in HT also helps distinguish it from HCC. The immunohistochemical differences between HT and both HYST
and HCC also bolster the evidence that HT is a distinct lesion.

Well-differentiated liver tissue in testicular teratomas
is exceedingly rare. Nakashima et al19 examined 516 germ
cell tumors of diverse origin for the presence of hepatic

Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
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FIGURE 4. HTs showing strong positive immunoreactivity for glypican-3 (A), HepPar-1 (B), arginase (C), and focal positivity in
biliary ductules for cytokeratin 19 (D).

tissue and found 7 testicular cases in young men; 5 of these
cases also contained YST, and none showed a mature
hepatic phenotype. It is unclear if some or all of their cases
represent hepatoid differentiation of YST rather than a

134 | www.ajsp.com

teratoma, but in none were portal triads found. Jain et al20
reported a mixed testicular germ cell tumor with foci of
HCC showing inﬁltrative growth and overt cytologic
atypia. We have not seen the development of a bona ﬁde
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
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TABLE 3. Clinicopathologic Characteristics of the HCC Control Group (N = 16)
Case
No.

Age
(y)

Sex

1

55

Male

Partial
hepatectomy

Right

3.6

No

Moderate

2

60

Male

Right

3.9

No

Moderate

3

49

Male

Right/left

3.2

Yes

Well

4

69

Male

Partial
hepatectomy
Total
hepatectomy
Partial
hepatectomy

Left

20

No

Moderate

5

67

Male

Right

3

No

Moderate

6

65

Male

Left

1.2

Yes

Well

7

79

Male

Right

10.4

Yes

Poor

8

63

Male

Left

7.7

Yes

Well

9

71

Right

10

No

Moderate

10

65

Right

5.5

No

Well

11

55

Left

24.5

No

Well

12

60

Male

Total
hepatectomy

Right

5

Yes

Moderate

13

51

Male

Total
hepatectomy

Right

3.2

No

Well

Cirrhosis, cholestasis

14

55

Right

20

Yes

Moderate

Cirrhosis (radiologic)

15

73

Male

Biopsy

Left

9.6

No

Moderate

Noncirrhotic
(radiologic)

16

64

Male

Total

Right

3

Yes

Well

Specimen

Total
hepatectomy
Total
hepatectomy
Partial
hepatectomy

Partial
hepatectomy
Male Partial
hepatectomy
Male Partial
hepatectomy
Female Partial
hepatectomy

Female Biopsy

Location Size
Degree of
(Lobe) (cm) Multifocality Differentiation

Background Liver
(Nontumoral)

Prominent Light Microscopic
Features

Cirrhosis

Trabecular and pseudoacinar
architecture, clear cell
features, steatosis
Steatohepatitis, cirrhosis Trabecular architecture
(radiologic)
Cirrhosis
Trabecular and pseudoacinar
architecture
Cirrhosis
Trabecular and pseudoacinar
architecture, Mallory-Denk
bodies
Cirrhosis
Trabecular architecture, clear
cell features
Cirrhosis, HCV
Pseudoacinar architecture,
Mallory-Denk bodies
Ductular reaction
Trabecular architecture, clear
cell features, Mallory-Denk
bodies
Bridging ﬁbrosis, HCV Pseudoacinar architecture
Mild steatosis
Mild portal
inﬂammation
Chronic portal
inﬂammation, ductal
plate malformation
Cirrhosis, HCV

Cirrhosis, NASH

Trabecular and pseudoacinar
architecture
Trabecular architecture,
Mallory-Denk bodies
Pseudoacinar architecture,
steatosis
Trabecular and pseudoacinar
architecture, Mallory-Denk
bodies
Trabecular and pseudoacinar
architecture, Mallory-Denk
bodies
Trabecular and pseudoacinar
architecture, hyalinized bands
Trabecular and pseudoacinar
architecture, steatosis,
Mallory-Denk bodies
Pseudoacinar architecture,
steatosis, Mallory-Denk
bodies

HCV indicates hepatitis C virus; NASH, nonalcoholic steatohepatitis.

HCC in a testicular germ cell tumor. Presumably, such a
case would show the usual features of liver-based HCC
and the immunohistochemical properties we found in this
study. Clearly, the distinction of such a case from usual
HCC must rely on the association with germ cell tumor
elements and/or distribution of any secondary deposits.
Regardless, the ﬁndings in both studies contrast with those
of the 2 HTs we herein report. In our review of the literature, we could ﬁnd no comparable case of postpubertaltype teratoma of testicular germ cell tumor origin that
showed an organoid hepatic phenotype.
In summary, HT is a rare lesion that may be found in
postchemotherapy specimens of patients with testicular germ
cell tumors and that has unique morphologic and immunohistochemical ﬁndings contrasting with those of its 2
potential mimickers—HYST and HCC. It is important to
make its distinction from these more prognostically ominous
neoplasms, which often require quite different management.
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